Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.
Major finding: Patients reported an average decrease of 10.9 MHDs ( P less than .001) after onabot treatment and a further decrease of 5.7 MHDs ( P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs ( P less than .001) with combined therapy. No serious adverse events were reported.
Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.
Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.
Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093 .